NEJM

A landmark NEJM trial found Dexcom G7 glucose monitors cut A1C by 1.6% in type 2 diabetes patients not on insulin, adding five hours a day in range.

A clinical trial found optogenetic vision therapy partly restored sight in blind patients with retinitis pigmentosa; six of 10 gained meaningful vision.